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Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and 
JAK2V617F negative chronic myeloproliferative disorders. 
 
To the Editor 
 
BCR-ABL negative Chronic Myeloproliferative Disorders (CMPDs) are a heterogeneous group 
of clonal haematological malignancies characterised by an abnormal proliferation and survival of one 
or more myeloid lineage cells that evolve in some cases to an acute myeloid leukemia (AML). These 
diseases include both classic CMPDs like essential thrombocythemia (ET), polycythaemia vera (PV) 
and idiopathic myelofibrosis (IMF), and atypical CMPDs (like chronic eosinophilic leukaemia and 
others). Unlike CML, in which BCR-ABL fusion seems to be the primary cause of the disease, the 
pathogenesis of the other CMPDs have remain elusive until recently. In last years, some genetic 
alterations have been described, mainly activating some tyrosine kinase genes (like JAK2 in classic 
CMPDs, but also FGFR1, PDGFRA and PDGFRB in some atypical CMPDs) but also some of them in 
genes (like MPL) involved in the same signal transduction pathways mediated by the TKs mutated. Of 
all of these, only V617F mutation in JAK2 has been found highly recurrent in classic CMPDs and in a 
minor proportion of atypical CMPDs. 
The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signalling 
pathway plays a vital role in myeloid differentiation. Cytokines and growth factors bind to the 
membrane receptors activating a nonreceptor tyrosine kinase, JAK. As noted aboved, one of the four 
JAKs genes, JAK2, has been found mutated in a high proportion of classic CMPDs, and also the gene 
coding for the thrombopoietin receptor (MPL) has been found mutated in some cases with IMF. Once 
activated JAK, a specific STAT transcription factor is phosphorylated and dimerizes, resulting in 
transactivation of target genes. Suppressors of cytokine signalling (SOCS) family proteins including 
SOCS1 and SOCS3 are simultaneously activated and directly interact with JAK in normal cells, 
resulting in the inhibition of STAT phosphorylation. Thus, SOCS proteins inhibit signal transduction 
of cytokines and growth factors. 
SOCS1 seems to act as a tumor suppressor gene. In fact, methylation and inactivation of this 
gene has been observed in a variety of human cancers, including around 60% of newly diagnosed 
AML (1). CML patients also show SOCS1 methylation that reverts to an unmethylated state during 
remission (2). SOCS3 is also frequently methylated and silenced in various cancer types, like human 
lung cancer (3) and human hepatocelular carcinoma (HCC) (4). Takeuchi et al (5) showed that 
expression of SOCS3 mRNA in bone marrow cells from CML patients was inversely associated with 
cytogenetic response to IFN-α.  
The aim of this study was to determine the methylation status of CpG islands of SOCS1 and 
SOCS3 genes in CMPD patients under the hypothesis that JAK/STAT pathway could be deregulated 
in these diseases. The methylation status of 39 CMPD samples was analyzed for SOCS1 (promoter and 
two regions in exon 2) and for SOCS3 (three regions in the promoter). All patients were found to be 
negative to V617F mutation on JAK2, by cytogenetics and molecular genetics analysis methods at the 
time of diagnosis. DNA from more than 20 healthy volunteers was used as control samples. 
Primers for the promoter region of SOCS1 were reported previously (6); exon 2 primers 
(regions 1 and 2) of SOCS-1 were designed by us. SOCS3 primers (three regions) were described by 
Niwa and colleagues (4): the first set covers two STAT-binding sites that localize upstream to any of 
the identified transcription start sites [consensus STAT-binding sequence: TT(N)5AA]; the second set 
spans a DNA region containing three transcription start sites (the second through fourth), and the third 
set is able to assess DNA methylation in the region containing the third STAT-binding site. PCR 
products were analyzed on 2% agarose gel. 
The promoter region of SOCS1 was found to be unmethylated in both patient and control 
samples of our series. Liu et al (2) studied SOCS1 promoter in a CML group and found aberrant 
hypermethylation in 52% (52/100) of blastic and chronic phase CML samples but no 
hypermethylation in normal controls or CML in molecular remission. Their results were consistent 
with the expression analyses. However Hatirnaz et al (7) have recently studied SOCS1 promoter and 
exon 2 on 56 CML samples and 16 normal samples. They have not detected aberrant methylation in 
SOCS1 promoter, the same region analyzed by Liu et al (2). The reasons for this discrepancy proposed 
by Hatirnaz et al (7) are the different selection of CpG island prediction methods, differences in PCR 
specificity and efficiency, or a different patient selection criteria and sampling time points. 
In contrast, region 1 in SOCS1 exon 2 was found to be methylated in a high percentage of both 
patient and control groups (72.2 % and 85.2 % respectively, Table 1). In addition, our region 2 in 
SOCS1 exon 2 was unmethylated in patients, and methylated in 8.1% of normal individuals (Table 2). 
Johan et al (8) and Hatirnaz et al (7) have also studied the methylation status of exon 2 in AML (40 %, 
19/47) and CML (58.9 %, 33/56) respectively, and they have also found methylation in normal 
controls although in very different proportions (13%, 2/15 and 93.8%, 15/16 respectively). Our results 
show an important frequency of methylation in healthy controls as observed by Hatirnaz et al and no 
differences were observed with CMPDs samples, supporting the hypothesis that exon 2 is not a 
pathogenetically relevant region in the study of SOCS1 methylation status. 
Hatirnaz et al (7) found SOCS1 Exon 2 methylated in 15 of 16 healthy controls. We also 
detected higher methylation in the control group than in patients (Tables 1 and 2). Since the 
methylation status of Exon 2 is higher in healthy controls than in patients, a hypomethylation status 
could be speculated in the region studied (7). This hypothesis should be validated across a larger group 
of healthy individuals, and the results should be confirmed with gene expression and mutation 
analyses. 
Region 1 of SOCS3 was methylated in 5,3 % (2/38) individuals of the control group and in 7,7 
% (3/39) of the CMPDs patients (Table 3). Region 2 of SOCS3 was found to be completely 
unmethylated in both patient and control groups. Both results are very different to the dense 
methylation observed previously in these two regions in non small cell lung cancer (NSCLC) cell lines 
(3). 
However, the methylation status of the third region of SOCS3 seems to be relevant in CMPDs. 
We have observed methylation in 23,1 % (9/39) of the CMPDs patients, but in only 5,1 % (2/39) of 
the control healthy donors [OR= 5,5; (1,114;27,656) 95% CI; P=0.023] (Table 4). This result indicates 
a significant association between methylated status of the region 3 of SOCS3 gene and the CMPD 
patient group. 
In fact, Niwa et al (4) also found methylation in this region 3 of SOCS3 both in three of the 10 
HCC cell lines analyzed and in 33.3% (6/18) HCC primary samples but not in normal samples. In 
addition, this methylation was associated with subsequent SOCS3 silencing. 
As far as we know, there are no previous reported epigenetic studies of SOCS1 and SOCS3 
genes of BCR-ABL and JAK2V617F negative CMPD patients. Our results on methylation status of 
region 3 of SOCS3 in these patients are consistent with the results obtained in HCC (4), and support 
the idea that the analysis of the third region of SOCS3 is the most relevant for malignant lesions. This 
hypothesis should be confirmed in other cancer types, and completed with expression studies, in order 
to firmly establish its significance in the pathogenesis of these diseases.  
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Table 1. Methylation status of SOCS1 Exon 2 Region 1 
  
CMPD 
patients 
(n=36) 
Healthy 
controls 
(n=27) 
P 
 
OR IC 95% 
SOCS1 Exon 2 
Region 1     
 
 Unmethylated 10 (27,8%) 4 (14,8%) 0,22 0,45 (0,13;1,64) 
 Methylated 26 (72,2%) 23 (85,2%)    
 
Table 2. Methylation status of SOCS1 Exon 2 Region 2 
  
CMPD 
patients 
(n=39) 
Healthy 
controls 
(n=37) 
P 
 
OR IC 95% 
SOCS1 Exon 2 
Region 2     
 
 Unmethylated 39 (100%) 34 (91,9%) 0,11 Not Computable Not Computable 
 Methylated 0 (0%) 3 (8,1%)    
 Table 3. Methylation status of SOCS3 Region 1 
  
CMPD 
patients 
(n=39) 
Healthy 
controls 
(n=38) 
P 
 
OR IC 95% 
SOCS3 Region 1      
 Unmethylated 36 (92,3%) 36 (94,7%) 1,00 1,50 (0,24;9,52) 
 Methylated 3 (7,7%) 2 (5,3%)    
 
Table 4. Methylation status of SOCS3 Region 3 
  
CMPD 
patients 
(n=39) 
Healthy 
controls 
(n=39) 
P 
 
OR IC 95% 
SOCS3 Region 3      
 Unmethylated 30 (76,9%) 37 (94,9%) 0,02 5,55 (1,11;27,66) 
 Methylated 9 (23,1%) 2 (5,1%)    
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